Immunosuppression, although necessary to enable the graft to escape the consequences of
immune surveillance, carries some risks for the patient. There is an associated increase in
neoplasms, opportunistic infections and end-organ toxicity In addition, even with excellent
patient compliance, rejection (acute and chronic) remains a major limitation that contributes
to the loss or decrease in the function of the allograft. New drugs have been added to the
armamentarium of immunosuppressive agents to suppress allograft rejection and to rescue …